AGIR à dom.
Meylan, 38240, France
NCT Number: NCT04506216
The purpose of this study is to determine the prevalence of eating disorders in type 1 insulin-dependent diabetes patients
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Meylan, 38240, France
The risk of developing an eating disorder is increased in type 1 diabetes patients and associated with a poor prognosis in terms of glycemic control, metabolic complications, degenerative complications, and mortality.
Therefore the terminology diaboulimia has emerged to characterize an eating disorder specific to type 1 insulin-dependent diabetes patients, with insulin under dosage with a view of losing or controlling weight and that can contribute to a deterioration of the body composition.
The purpose of this study is to determine the prevalence of eating disorders in an adult cohort with type 1 insulin-dependent diabetes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
During a regular follow-up visit, the following data will be collected:
Time frame: at inclusion
To determine eating disorder prevalence in differentiated adult men and women with type 1 insulin-dependent diabetes.
Patients answer to the SCOFF-F questions :
Every "yes" attributes one point and gives a final score between 0 and 5; a score ≥2 indicates an eating disorder.
Time frame: at inclusion
To determine eating disorder prevalence in undifferentiated cohort (men and woman) with type 1 insulin-dependent diabetes.
Patients answer to the SCOFF-F questions :
Every "yes" attributes one point and gives a final score between 0 and 5; a score ≥2 indicates an eating disorder.
Time frame: at inclusion
To Determine the auto declared insulin under dosage prevalence in undifferentiated cohort (men and woman) with type 1 insulin-dependent diabetes.
Patients answer to the 5th m-SCOFF question :
A "yes" answer means that patient underdoses insulin treatment.
Time frame: at inclusion
To identify if there is a link between an eating disorder and overall glycemic control, we will look after the last biological value of HbA1c rates
Time frame: at inclusion
To identify if there is a link between an eating disorder and basal/bolus insulin ratio, we will extract and compare to eating disorder presence, this daily data from insulin pump over the 14 days preceding inclusion
Time frame: at inclusion
To identify if there is a link between an eating disorder and boluses performed per day, we will extract and compare to eating disorder presence, this daily data from insulin pump over the 14 days preceding inclusion
Time frame: at inclusion
To identify if there is a link between an eating disorder and body composition, we will perform a bio-electric impedance analysis and compare the result to eating disorder presence.
Time frame: at inclusion
To identify if there is a link between an eating disorder and continuous glycemic control, we will extract and compare to eating disorder presence, this data from the continuous glucose monitoring system (CGMS) over the 14 days preceding inclusion Glycemic control will be determined by the percentage of daily time into the glycemic target (between 70 and 180 mg/dL).
Time frame: at inclusion
To identify if there is a link between an eating disorder and glycemic variability, we will extract and compare to eating disorder presence, this data from the continuous glucose monitoring system (CGMS) over the 14 days preceding inclusion Glycemic variability will be determined by the Mean Amplitude of Glycemic Excursions (MAGE) algorithm.
Time frame: at inclusion
To identify if there is a link between an eating disorder and the adherence to the continuous glucose monitoring system (CGMS), we will extract and compare to eating disorder presence, this data from the continuous glucose monitoring system (CGMS) over the 14 days preceding inclusion Adherence will be determined by the number of minutes worn per day.
Time frame: at inclusion
To identify if there is a link between an eating disorder and blood glucose monitoring, we will extract and compare to eating disorder presence, this data from the continuous glucose monitoring system (CGMS) over the 14 days preceding inclusion The monitoring will be determined by the number of scans done per day.
Icadom
Industry
Prevalence of Eating Disorders in Adult Patients With Type I Diabetes and Insulin Pump Treatment
Acronym: Diaboulimia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05264376
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT05540704
Autoimmune Diseases, Behavior
Durham, North Carolina, United States
View Trial DetailsNCT05399446
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT05546281
Autoimmune Diseases, Behavior
Québec, Canada
View Trial Details